Scholarlink

Objective <p>The aim of this study was to investigate physicians’ perspectives on the tapering and discontinuation (R&amp;D) of antidepressants (AD) and antipsychotics (AP).</p> Methods <p>In ten systematic interviews and a&#xa0;focus group with outpatient psychiatrists from Berlin and Brandenburg, differences in assessments, counseling practices, and decision-making patterns were recorded and subsequently with MAXQDA inductively evaluated.</p> Results <p>R&amp;D is initiated more frequently in AD because depressed patients are considered more insightful and adherent to treatment. In contrast, psychiatrists perceive the risk of relapse and the consequences of discontinuing AP to be higher, leading to more reluctance to initiate R&amp;A. Structural barriers, unclear guidelines, and a&#xa0;lack of non-pharmacological alternatives make R&amp;A difficult, particularly in cases of psychosis.</p> Conclusion <p>More participatory R&amp;D practices require clear guidelines, knowledge transfer, and improved psychosocial care services—especially for patients with psychosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reduzieren und Absetzen von Antipsychotika und Antidepressiva: Vergleichende Bewertung durch ambulante Psychiater*innen

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月18日

查看全文
  • Thomas Koch,
  • Sebastian von Peter,
  • Stefan Weinmann,
  • Guillermo Ruiz-Pérez

摘要

Objective

The aim of this study was to investigate physicians’ perspectives on the tapering and discontinuation (R&D) of antidepressants (AD) and antipsychotics (AP).

Methods

In ten systematic interviews and a focus group with outpatient psychiatrists from Berlin and Brandenburg, differences in assessments, counseling practices, and decision-making patterns were recorded and subsequently with MAXQDA inductively evaluated.

Results

R&D is initiated more frequently in AD because depressed patients are considered more insightful and adherent to treatment. In contrast, psychiatrists perceive the risk of relapse and the consequences of discontinuing AP to be higher, leading to more reluctance to initiate R&A. Structural barriers, unclear guidelines, and a lack of non-pharmacological alternatives make R&A difficult, particularly in cases of psychosis.

Conclusion

More participatory R&D practices require clear guidelines, knowledge transfer, and improved psychosocial care services—especially for patients with psychosis.